Producing amorphous form of compound e.g. dasatinib for providing antitumor effect, by preparing solution of compound in dimethyl sulfoxide, adding tert-butanol, filtering, cooling, freeze-drying, removing dimethyl sulfoxide, and confirming
2023-06-21
专利权人ZOLOTOV S A (ZOLO-Individual) ; DAIN I A (DAIN-Individual) ; PONOMAREV E S (PONO-Individual) ; SAZONOV G K (SAZO-Individual) ; ZOLOTOVA A S (ZOLO-Individual)
申请日期2023-06-21
专利号RU2023116344-A
成果简介NOVELTY - Method for producing an amorphous form of a compound chosen from dasatinib, ibrutinib, nilotinib or nilotinib hydrochloride, sorafenib tosylate, pomalidomide and lapatinib ditosylate monohydrate involves (a) preparing a solution of the compound in dimethyl sulfoxide with a concentration of 40 mg/ml, (b) adding 10-20 vol.% tert-butanol to the obtained solution with stirring, (c) filtering the obtained solution through a hydrophilic filter, (d) cooling the resulting filtrate to -40° C and freeze-drying, and raising at 0° C, (e) removing dimethyl sulfoxide from the dried product to a residual content of ≯ 0.5%, and (f) confirming the production of amorphous form of the compound by X-ray powder diffraction. USE - The method is useful for producing amorphous form of the compound chosen from dasatinib, ibrutinib, nilotinib or nilotinib hydrochloride, sorafenib tosylate, pomalidomide and lapatinib ditosylate monohydrate for providing antitumor effect.
IPC 分类号C07D-277/56
国家俄罗斯
专业领域化学化工
语种英语
成果类型专利
文献类型科技成果
条目标识符http://119.78.100.226:8889/handle/3KE4DYBR/21547
专题中国科学院新疆生态与地理研究所
作者单位
1.ZOLOTOV S A (ZOLO-Individual)
2.DAIN I A (DAIN-Individual)
3.PONOMAREV E S (PONO-Individual)
4.SAZONOV G K (SAZO-Individual)
5.ZOLOTOVA A S (ZOLO-Individual)
推荐引用方式
GB/T 7714
ZOLOTOV S A,DAIN I A,PONOMAREV E S,et al. Producing amorphous form of compound e.g. dasatinib for providing antitumor effect, by preparing solution of compound in dimethyl sulfoxide, adding tert-butanol, filtering, cooling, freeze-drying, removing dimethyl sulfoxide, and confirming. RU2023116344-A[P]. 2023.
条目包含的文件
条目无相关文件。
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。